J.P. Morgan analyst Tycho Peterson maintained a Buy rating on Qiagen (QGEN) yesterday. The company’s shares closed last Tuesday at $50.35.
According to TipRanks.com, Peterson is a 5-star analyst with an average return of 14.7% and a 66.3% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Intuitive Surgical, and Envista Holdings.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $57.46, which is a 14.1% upside from current levels. In a report issued on November 25, Kepler Capital also upgraded the stock to Buy with a EUR51.00 price target.
See today’s analyst top recommended stocks >>
Based on Qiagen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $484 million and net profit of $16.91 million. In comparison, last year the company earned revenue of $383 million and had a GAAP net loss of $161 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
